Edition:
India

Roche Says New Data Further Shows Ocrevus’ Effectiveness


Friday, 11 Sep 2020 

Sept 11 (Reuters) - Roche Holding AG ::NEW DATA FURTHER REINFORCE ROCHE’S OCREVUS (OCRELIZUMAB) AS A HIGHLY EFFECTIVE TREATMENT FOR PEOPLE WITH MULTIPLE SCLEROSIS.NEW DATA SHOW OCREVUS® (OCRELIZUMAB) IS A HIGHLY EFFECTIVE TREATMENT OPTION FOR PEOPLE WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) WHO EXPERIENCED A SUBOPTIMAL RESPONSE TO THEIR PRIOR DISEASE MODIFYING THERAPY (DMT).75% OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) AND SUBOPTIMAL RESPONSE TO PRIOR TREATMENT HAD NO EVIDENCE OF DISEASE ACTIVITY TWO YEARS AFTER SWITCHING TO OCREVUS IN OPEN-LABEL PHASE IIIB CASTING STUDY.OCREVUS IS FIRST AND ONLY TREATMENT APPROVED FOR BOTH RELAPSING MS (RMS) AND PRIMARY PROGRESSIVE MS (PPMS).MORE THAN 170,000 PEOPLE HAVE BEEN TREATED WITH OCREVUS GLOBALLY IN CLINICAL TRIAL AND REAL-WORLD SETTINGS. 

Company Quote

41.225
-0.455 -1.09%
23 Nov 2020